Dow University of Health Sciences
20 imported, source-linked research records. Open-access records.
20 matching research records
Topic: Canagliflozin and SGLT2. Only records linked to Dow University of Health Sciences are included. Historical ingestion is still running; these are imported records, not a count of all research worldwide.
Showing 1–20 of 20 matching records. Counts update as records arrive.
Effectiveness of Adding GLP ‐1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study
September 27, 2026 · 0 citations · Open access
Open original record →GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis
June 26, 2026 · 0 citations · Open access
Open original record →Clinical Outcomes of GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Heart Failure: A Real-World Propensity-Matched TriNetX Analysis
June 17, 2026 · 0 citations · Open access
Open original record →In-Hospital Initiation of SGLT2 Inhibitors in Patients with Acute Heart Failure: A Meta-analysis of Randomized Controlled Trials with Trial Sequential Analysis
April 1, 2026 · 0 citations · Open access
Open original record →Efficacy of SGLT2 Inhibitors on Clinical Outcomes After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta‐Analysis
February 26, 2026 · 6 citations · Open access
Open original record →Cardiac Remodeling Post-myocardial Infarction: Novel Therapies—Narrative Review
February 14, 2026 · 0 citations · Open access
Open original record →Assessing the Real-World Impact of Empagliflozin on Heart Failure with Reduced Ejection Fraction (HFrEF) Outcomes Irrespective of Diabetes Status
October 2, 2025 · 0 citations · Open access
Open original record →Comparative Effectiveness of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors Versus Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) in Heart Failure With Reduced Ejection Fraction: A Systematic Review
April 29, 2025 · 2 citations · Open access
Open original record →Cardiovascular outcomes and safety assessment of SGLT2i on heart failure patients: a systematic review and meta-analysis
January 18, 2025 · 1 citations · Open access
Open original record →Novel FDA-approved bexagliflozin drug for treating type 2 diabetes mellitus
October 4, 2024 · 2 citations · Open access
Open original record →Relationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysis
September 30, 2024 · 10 citations · Open access
Open original record →Efficacy of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure Management: A Narrative Review
September 29, 2024 · 0 citations · Open access
Open original record →Association Between SGLT2 Inhibitors and Risk of Dementia and Parkinson's Disease: A Meta-Analysis of 12 Randomized Controlled Trials
July 6, 2024 · 26 citations · Open access
Open original record →The effect of SGLT2 inhibitors on health status in patients with heart failure: a systematic review and meta-analysis
June 28, 2024 · 10 citations · Open access
Open original record →Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention
March 28, 2024 · 20 citations · Open access
Open original record →Navigating the Crossroads: Understanding the Link Between Chronic Kidney Disease and Cardiovascular Health
December 30, 2023 · 33 citations · Open access
Open original record →Novel Therapies in Diabetes: A Comprehensive Narrative Review of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Beyond
December 27, 2023 · 23 citations · Open access
Open original record →Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management
September 30, 2023 · 60 citations · Open access
Open original record →Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in COVID-19-infected patients: A systematic review of case reports
August 22, 2023 · 7 citations · Open access
Open original record →The dual role of empagliflozin: Cardio renal protection in T2DM patients
September 1, 2022 · 12 citations · Open access
Open original record →